| Southern Med Review | |
| Making the investment case for national regulatory authorities | |
| article | |
| Twesigye, Gloria1  Hafner, Tamara1  Guzman, Javier1  | |
| [1] USAID Medicines, and Pharmaceutical Services (MTaPS) Program, Management Sciences for Health | |
| 关键词: Regulatory systems; National regulatory authorities; Health systems strengthening; Access to medicines; Quality-assured medicines; | |
| DOI : 10.1186/s40545-021-00299-7 | |
| 学科分类:药理学 | |
| 来源: BioMed Central | |
PDF
|
|
【 摘 要 】
Well-functioning national regulatory authorities (NRAs) ensure access to safe, effective, quality-assured, and affordable medical products. However, the benefits of their work are often unseen and difficult to attribute, thereby making NRAs undervalued and under-resourced, particularly in low- and middle-income countries. This paper offers three key arguments NRAs and other stakeholders can use to advocate for greater investment in regulatory systems strengthening—medical products regulation effectively safeguards public health; effective regulation improves health system’s efficiency by increasing access to affordable medical products, contributing to universal health coverage; and robust regulation strengthens local pharmaceutical manufacturing and bolsters pharmaceutical trade. NRAs’ critical role in health systems is indisputable, yet they need to better promote their value to receive the requisite resources to function effectively.
【 授权许可】
Unknown
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202108090002418ZK.pdf | 669KB |
PDF